Tocotrienol: A review of its therapeutic potential

Clinical Biochemistry

Volumn 32, Issue 5, 1999, Pages 309-319

  Theriault, Andre ^a   Chao, Jun Tzu ^a   Wang, Qi ^a   Gapor, Abdul ^b   Adeli, Khosrow ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b Palm Oil Research Institute of Malaysia   (Malaysia)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer; Cardiovascular disease; Tocopherol; Tocotrienol; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTICOAGULANT AGENT; ANTIOXIDANT; APOLIPOPROTEIN B; BETA TOCOPHEROL; DELTA TOCOPHEROL; GAMMA TOCOPHEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOXANE;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CELL ADHESION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LIPID PEROXIDATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; VITAMIN E;

EID: 0032849965     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00027-2     Document Type: Review

References (98)

1. Kamal-Eldin A., Appelqvist L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids. 31:1996;671-701.
2. Meydani M. Vitamin E. Lancet. 345:1995;170-175.
3. Ames B.N., Gold L.S., Willett W.C. The cause and prevention of cancer. Proc Natl Acad Sci USA. 2:1995;5258-5265.
4. Combs G.F. Jr. The vitamins fundamental aspects in nutrition and health . 1992;Academic Press Inc, San Diego.
5. Hood R.L. Tocotrienols and cholesterol metabolism. Ong A.S.H., Niki E., Packer L. Nutrition, lipids, health, and disease. 1996;96-103 AOCS Press, Champaign, IL.
6. Carroll KK, Cuthrie N, Nesaretnam K, Gapor A, Chambers AF. Anti-cancer properties of tocotrienols from palm oil. In: Ong ASH, Niki E, Packer L, Eds. Nutrition, lipids, health, and disease. Pp. 117-21. Champaign, IL: AOCS Press, 1996.
7. 1998 Heart and Stroke Statistical Update. American Heart Association (1997), Dallas.
8. The lipid research clinics coronary primary prevention trial results I reduction in incidence of coronary heart disease . JAMA. 251:1984;351-364.
9. National Center for Health Statistics (NCHS). Annual summary of births, marriages, divorces, and deaths: United States, 1990. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, CDC, 1991. (Monthly vital statistics report: 39(13).).
10. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 328:1993;1444-1449.
11. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in man. N Engl J Med. 328:1993;1450-1456.
12. Hodis H.N., Mack W.J., LaBree L. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 273:1995;1849-1854.
13. Kushi L.H., Foldom A.R., Prineas R.J. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 334:1996;1156-1162.
14. Stephens N., Parsons A., Schofield P., Kelly F., Cheeseman K., Mitchinson M. Randomized controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
15. Esterbauer H., Bieber-Rotheneder M., Striegel G., Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr. 3:1991;314S-321S.
16. Salonen J.T., Yla-Herttuala S., Yamamoto R. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
17. Salonen J.T., Salonen R., Penttila I., et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol. 56:1985;226-231.
18. Kok F., de Bruijn A., Vermeeren R., et al. Serum selenium, vitamin antioxidants and cardiovascular mortality a 9-year follow-up study in the Netherlands . Am J Clin Nutr. 45:1987;462-468.
19. Hense H.W., Stender M., Bors W., Keil U. Lack of an association between serum vitamin E and myocardial infarction in a population with high vitamin E levels. Atherosclerosis. 103:1993;21-28.
20. Qureshi A.A., Qureshi N., Wright J.J.K., et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr. 53:1991;1021S-1026S.
21. Qureshi A.A., Bradlow B.A., Brace L., et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids. 30:1995;1171-1177.
22. Qureshi A.A., Bradlow B.A., Salser W.A., Brace L.D. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. Nutr Biochem. 8:1997;290-298.
23. Tomeo A.C., Geller M., Watkins T.R., Gapor A., Bierenbaum M.L. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids. 30:1995;1179-1183.
24. Qureshi A.A., Burger W.C., Peterson D.M., Elson C.E. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. J Biol Chem. 261:1986;10544-10550.
25. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
26. Correll C.C., Ng L., Edwards P.A. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 269:1994;17390-17393.
27. Qureshi A.A., Qureshi N., Halser-Rapacz J.O., et al. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. Am J Clin Nutr. 53:1991;1042S-1046S.
28. Pearce B.C., Parker R.A., Deason M.E., Qureshi A.A., Wright J.J.K. Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem. 35:1992;3595-3606.
29. Pearce B.C., Parker R.A., Deason M.E., et al. Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydroaphthalene analogues of the tocotrienols. J Med Chem. 37:1992;526-541.
30. Qureshi A.A., Pearce C., Nor R.M., Gapor A., Peterson D.M., Elson C.E. Dietary α-tocopherol attenuates the impact of γ-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens. J Nutr. 126:1996;389-394.
31. Albers J.J., Brunzell J.D., Knopp R.H. Apoprotein measurements and their clinical application in cholesterol screening. Clin Lab Med. 34:1989;B4-B8.
32. Sniderman A., Shapiro S., Marpole D., Skinner B., Teng B., Kwiterovich P.O. Association of coronary atherosclerosis with hyperbetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low-density (beta) lipoproteins]. Proc Natl Acad Sci USA. 77:1980;604-608.
33. Brown G., Albers J.J., Fisher L.D. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
34. Bestehorn H.P., Rensing U.F., Roskamm H., et al. The effect of simvastatin on progression of coronary artery disease. Eur Heart J. 18:1997;226-234.
35. Parker R.A., Pearce B.C., Clark R.W., Gordon D.A., Wright J.J.K. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-Hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 268:1993;11230-11238.
36. Wang Q., Theriault A., Gapor A., Adeli K. Effects of tocotrienol on the intracellular translocation and degradation of apolipoprotein B possible involvement of a proteasome independent pathway . Biochem Biophys Res Commun. 246:1998;640-643.
37. Theriault A., Wang Q., Gapor A., Adeli K. Effects of γ-tocotrienol on apolipoprotein B synthesis, degradation, and secretion in HepG2 cells. Arterioscler Thromb Vasc Biol. 19:1999;704-712.
38. Maher V.M.G., Brown B.G. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 6:1995;229-235.
39. Scanu A.M., Fless G.M. Lipoprotein(a) heterogeneity and biological relevance . J Clin Invest. 86:1990;1709-1715.
40. Naruszewicz M., Selinger E., Davignon J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism. 41:1992;1215-1224.
41. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
42. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 339:1989;301-303.
43. Yamaguchi H., Lee Y.J., Daida H. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA) LDL-apheresis angioplasty restenosis trial (L-ART) . Chem Phys Lipids. 67/68:1994;399-403.
44. Kanemitsu S., Tekekoshi N., Murakami E. Effects of LDL apheresis on restenosis after angioplasty. Chem Phys Lipids. 67/68:1994;339-343.
45. Jenner J.L., Ordovas J.M., Lamon-Fava S. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels the Framingham Offspring Study . Circulation. 87:1993;607-614.
46. Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM. Ed. Lipoprotein(a). Pp. 211-20. New York: Academic Press, 1990.
47. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med. 226:1989;271-276.
48. Pelegri A., Romero R., Senti M., Nogues X., Pedro-Botet J., Rubies-Prat J. Effect of bezafibrate on lipoprotein(a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant. 7:1992;623-626.
49. Farmer J.A., Gotto A.M. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab. 9:1995;825-847.
50. Hirsh J. Hyperactive platelets and complications of coronary artery disease. N Engl J Med. 316:1987;1543-1544.
51. Jandak J., Steiner M., Richardson P.D. α-Tocopherol, an effective inhibitor of platelet adhesion. Blood. 73:1989;141-149.
52. Romach E.R., Kidao S., Sanders B.G., Kline K. Effects of RRR-alpha-tocopheryl succinate on IL-1 and PGE2 production by macrophages. Nutr Cancer. 20:1993;205-214.
53. Meydani M., Meydani S.N., Blumberg J.B. Modulation by dietary vitamin E and selenium of clotting whole blood thromboxane A2 and aortic prostacyclin synthesis in rats. Nutr Biochem. 4:1993;322-326.
54. Douglas C.E., Chan A.C., Choy P.C. Vitamin E inhibits platelet phospholipase A2. Biochem Biophys Acta. 876:1986;639-645.
55. Traber M.G., Packer P. Vitamin E beyond antioxidant function . Am J Clin Nutr. 62:(Suppl):1995;1501S-1509S.
56. Appleby S., Ristimaki A., Neilson K., Narko K., Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J. 302:1994;723-727.
57. Steiner M., Glantz M., Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr. 62:(Suppl):1995;1381S-1384S.
58. Niki E., Kawakami A., Satio M., Yamamoto Y., Tsuchiya J., Kamiya Y. Effect of phytyl side chain of vitamin E on its antioxidant activity. J Biol Chem. 260:1985;2191-2196.
59. Burton G.W., Ingold K.U. Vitamin E as in vitro and in vivo antioxidant. Ann NY Acad Sci. 570:1989;7-22.
60. Burton G.W., Traber M.G. Vitamin E antioxidant activity, biokinetics and bioavailability . Ann Rev Nut. 10:1990;357-382.
61. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol modification of low-density lipoprotein that increases its atherogenicity . N Engl J Med. 320:1989;915-924.
62. Verlangeri A.J., Bush M. Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr. 11:1992;131-138.
63. Reaven P.D., Khouw A., Beltz W.F., Parthasarathy S., Witztum J.L. Effect of dietary antioxidant combinations in humans protection of LDL by vitamin E but not by beta-carotene . Arterioscler Thromb. 13:1993;590-600.
64. Burton G.W., Joyce A., Ingold K.U. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch Biochem Biophys. 221:1983;281-290.
65. Cooney R.V., Franke A.A., Harwood P.J., Hatch-Pigott V., Custer L.J., Mordan L.J. γ-Tocopherol detoxification of nitrogen dioxide Superiority to α-tocopherol . Proc Natl Acad Sci USA. 90:1993;1771-1775.
66. Serbinova E., Kagan V., Han D., Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of α-tocopherol and α-tocotrienol. Free Radic Biol Med. 10:1991;263-275.
67. Suzuki Y.J., Tsuchiya M., Wassall S.R., et al. Structural and dynamic membrane properties of α-tocopherol and α-tocotrienol implications to the molecular mechanism of their antioxidant potency . Biochemistry. 32:1993;10692-10699.
68. Kamat J.P., Devasagayam T.P.A. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neuro Lett. 195:1995;179-182.
69. Serbinova E., Khwaja S., Catudioc J., et al. Palm oil vitamin E protects against ischemia/reperfusion injury in the isolated perfused Langendorff heart. Nutr Res. 12:1992;S203-S215.
70. Carlos T.M., Harlan J.M. Leukocyte-Endothelial adhesion molecules. Blood. 84:1994;2068-2101.
71. Peter K., Lincoff A.M., Conradt C., et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol. 17:1997;505-512.
72. Blann A.D., McCollum C.N. Circulating endothelial cell leukocyte adhesion molecules in atherosclerosis. Thromb Haemost. 74:1994;151-154.
73. Schreck R., Albermann K., Baeuerle P.A. Nuclear factor κB an oxidative stress responsive transcription factor of eucaryotic cells (a review) . Free Radic Res Commun. 17:1992;221-237.
74. Khan B.V., Parthasarthy S.S., Alexander R.W., et al. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest. 95:1995;1262-1270.
75. Cominacini L., Garbin U., Pasini A.F., et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidizied LDL on human umbilical vein endothelial cells. Free Radic Biol Med. 22:1997;117-127.
76. Devaraj S., Li D., Jialal I. The effects of alpha tocopherol supplementation on monocyte function Decreased lipid oxidation, interleukin 1βsecretion, and monocyte adhesion to endothelium . J Clin Invest. 98:1996;756-763.
77. Birt D.F. Update on the effects of vitamin A, C and E, and selenium on carcinogenesis. Proc Soc Exp Biol Med. 183:1986;311.
78. Bostick R.M., Potter J.D., McKenzie D.R., et al. Reduced risk of colon cancer with high intake of vitamin E The Iowa Women's Health Study . Cancer Res. 53:1993;4230-4237.
79. Taylor P.R., Li B., Dawsey S.M., et al. Prevention of eosophageal cancer the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group . Cancer Res. 54:(Suppl 7):1994;2029S-2031S.
80. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1994;1029-1035.
81. Ames B.N., Christen S., Hagen T.M., Shigenaga M.K. Infection, inflammation and mutation. Parsonnet J. Microbes and malignancy infection as a cause of human cancers . 1999;28-56 Oxford University Press, Oxford.
82. Serbinova E.A., Tsuchyia M., Goth S., Kagan V.E., Packer L. Antioxidant action of α-tocopherol and α-tocotrienol in membranes. Packer L., Fuchs J. Vitamin E in health and disease. 1993;235-243 Marcel Dekker Inc, New York.
83. Watkins T., Lenz P., Gapor A., Struck M., Tomeo A., Bierenbaum M. γ-Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. Lipids. 28:1993;1113-1118.
84. Komiyama A.K., Iizuka K., Yamaoka M., Watanabe H., Tsuchiya N., Umezawa I. Studies on the biological activity of tocotrienols. Chem Pharm Bull. 37:1989;1369-1371.
85. Wan Ngah Z.W., Jarien Z., San Myint M., et al. Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorene in rats. Am J Clin Nutr. 53:1991;1076S-1081S.
86. Rahmat A., Ngah W.Z.W., Shamaan A., Gapor A., Kadir K.A. Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. Nutrition. 9:1993;229-232.
87. Nesaretnam K., Guthrie N., Chambers A.F., Carroll K.K. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids. 30:1995;1139-1143.
88. Guthrie N., Gapor A., Chambers A.F., Carroll K.K. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr. 127:1997;544S-548S.
89. Nesaretnam K., Stephen R., Dils R., Barbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespectively of estrogen receptor status. Lipids. 33:1998;461-469.
90. Turley J.M., Sanders B.G., Kline K. RRR-tocopheryl succinate modulation of human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Nutr Cancer. 18:1992;201-213.
91. Charpentier A., Groves S., Simmons M.M. RRR-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-β (TGF-β) by human breast cancer cells. Nutr Cancer. 19:1993;225-239.
92. Crowell P.L., Chang R.R., Ren Z.B., Elson C.E., Gould M.N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem. 266:1991;17679-17685.
93. Elson C.E., Yu S.G. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr. 124:1994;607-614.
94. Larner J., Jane J., Laws E., et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 21:1998;579-583.
95. Stone W.L., Papas A.M. Tocopherols and the etiology of colon cancer. J Natl Cancer Inst. 89:1997;1006-1014.
96. Christen S., Woodall A.A., Shigenaga M.K., Southwell-Keely P.T., Duncan M.W., Ames B.N. γ-Tocopherol traps mutagenic electrophiles such as NOx and complements α-tocopherol Physiological implications . Proc Natl Acad Sci USA. 94:1997;3217-3222.
97. Packer J.E., Slater T.F., Willson R.L. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature. 278:1979;737-738.
98. Gould M.N., Haag J.D., Kennan W.S., Tanner M.A., Elson C.E. A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. Am J Clin Nutr. 53:1991;1068S-1070S.